In studies [196] that assessed the effect of Beclin-1 and LC3 immunoreactivity in patients with confirmed multiple myeloma, it was shown that patients with high levels of Beclin-1 and LC3 immunoreactivity had significantly better overall survival, compared to patients with moderate or low Beclin-1 or LC3 immunoreactivity [196]. This evidence concerns the gene MAP1LC3A and AL amyloidosis.